on July 21, 2008
Published online before print July 21, 2008, doi: 10.1161/CIRCULATIONAHA.108.769489
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 6, 2008
From the Universitätsklinikum des Saarlandes, Klinik für Innere Medizin III (Kardiologie, Angiologie, Internistische Intensivmedizin) (I.K., M.K., T.M., M.B.), and Klinik für Pädiatrische Kardiologie (A.L.), Homburg/Saar, Germany; and Universitätsklinikum Tübingen, Abteilung Molekulare Pathologie, Institut für Pathologie (R.K., K.K.), and Abteilung Allgemeine Pathologie (B.B.), Tübingen, Germany. * To whom correspondence should be addressed. E-mail: i.kindermann{at}med-in.uni-saarland.de.
Background—The objective of this study was to identify the prognostic indicators in patients with suspected myocarditis who underwent endomyocardial biopsy. Methods and Results—Between 1994 and 2007, 181 consecutive patients (age, 42±15 years) with clinically suspected viral myocarditis were enrolled and followed up for a mean of 59±42 months. Endomyocardial biopsies were studied for inflammation with histological (Dallas) and immunohistological criteria. Virus genome was detected by polymerase chain reaction. The primary end point was time to cardiac death or heart transplantation. In 38% of the patients (n=69), the Dallas criteria were positive. Immunohistological signs of inflammation were shown in 50% (n=91). Genomes of cardiotropic virus species were detected in 79 patients (44%). During follow-up, 22% of the patients (n=40) reached the primary end point. Three independent predictors were identified for the primary end point, namely New York Heart Association class III or IV at entry (hazard ratio, 3.20; 95% confidence interval, 1.36 to 7.57; P=0.008), immunohistological evidence of inflammatory infiltrates in the myocardium (hazard ratio, 3.46; 95% confidence interval, 1.39 to 8.62; P=0.008), and Conclusions—For patients with suspected myocarditis, advanced New York Heart Association functional class, immunohistological signs of inflammation, and lack of
Accepted on June 2, 2008
Predictors of Outcome in Patients With Suspected Myocarditis
Ingrid Kindermann MD*,
-blocker therapy (hazard ratio, 0.43; 95% confidence interval, 0.21 to 0.91; P=0.027). Ejection fraction, left ventricular end-diastolic pressure, and left ventricular end-diastolic dimension index were predictive only in univariate, not in multivariate, analysis. Neither the Dallas criteria nor the detection of viral genome was a predictor of outcome.-blocker therapy, but not histology (positive Dallas criteria) or viral genome detection, are related to poor outcome.
Key words: biopsy • cardiomyopathy • immunohistochemistry • molecular biology • myocarditis
Related Article:
Circulation 2008 118: 607-608.
This article has been cited by other articles:
 |
|
 |
|
  J. C. Schultz, A. A. Hilliard, L. T. Cooper Jr, and C. S. Rihal Diagnosis and Treatment of Viral Myocarditis Mayo Clin. Proc., November 1, 2009; 84(11): 1001 - 1009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. T. Cooper The heat is off: immunosuppression for myocarditis revisited Eur. Heart J., August 2, 2009; 30(16): 1936 - 1939. [Full Text] [PDF]
|
|
|
|
|
|
V. Hombach, N. Merkle, J. Torzewski, J. M. Kraus, M. Kunze, O. Zimmermann, H. A. Kestler, and J. Wohrle Electrocardiographic and cardiac magnetic resonance imaging parameters as predictors of a worse outcome in patients with idiopathic dilated cardiomyopathy Eur. Heart J., August 2, 2009; 30(16): 2011 - 2018. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L.P. Caforio, F. Tona, A. Vinci, A. Ramondo, L. Cacciavillani, L. Leoni, S. Iliceto, F. Calabrese, G. Thiene, A. Angelini, et al. Myocarditis mimicking Takotsubo cardiomyopathy or Takotsubo cardiomyopathy with secondary inflammation?: reply Eur J Heart Fail, August 1, 2009; 11(8): 810 - 810. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Noutsias, S. Pankuweit, B. Maisch, D. Huzly, M. Enders, and S. Pollak Pathophysiological Mechanisms of Parvovirus B19 Infection J. Clin. Microbiol., July 1, 2009; 47(7): 2358 - 2359. [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Buja Evaluation of Recombinant {alpha}-Galactosidase A Therapy for Amelioration of the Cardiovascular Manifestations of Fabry Disease: An Important Role for Endomyocardial Biopsy Circulation, May 19, 2009; 119(19): 2539 - 2541. [Full Text] [PDF]
|
|
|
|
|
|
T. Yajima and K. U. Knowlton Viral Myocarditis: From the Perspective of the Virus Circulation, May 19, 2009; 119(19): 2615 - 2624. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Szalay, M. Sauter, M. Haberland, U. Zuegel, A. Steinmeyer, R. Kandolf, and K. Klingel Osteopontin: A Fibrosis-Related Marker Molecule in Cardiac Remodeling of Enterovirus Myocarditis in the Susceptible Host Circ. Res., April 10, 2009; 104(7): 851 - 859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. T. Cooper Jr. Myocarditis N. Engl. J. Med., April 9, 2009; 360(15): 1526 - 1538. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Mahrholdt and U. Sechtem Noninvasive differentiation between active and healed myocarditis by cardiac magnetic resonance: are we there yet? J. Am. Coll. Cardiol. Img., February 1, 2009; 2(2): 139 - 142. [Full Text] [PDF]
|
|
|
|
|
|
S. Heymans, E. Hirsch, S. D. Anker, P. Aukrust, J.-L. Balligand, J. W. Cohen-Tervaert, H. Drexler, G. Filippatos, S. B. Felix, L. Gullestad, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail, February 1, 2009; 11(2): 119 - 129. [Abstract] [Full Text] [PDF]
|
|